Pilot Study of Expanded, Activated Haploidentical Natural Killer Cell Infusions for Non-B Lineage Hematologic Malignancies and Solid Tumors is a PHASE1 clinical asset sponsored by St. Jude Children's Research Hospital in Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, T-Cell, Juvenile Myelomonocytic Leukemia Lymphoblastic, T-cell Lymphoblastic Lymphoma, Myelodysplastic Syndrome. SEO and diligence focus: Haploidentical donor derived natural killer cell infusion, Chemotherapy, CliniMACS, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.